Head-to-head evidence
GZR18 vs TG103
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
GZR18
Developed by Gan & Lee Pharmaceuticals
NCT06737042 · Phase 2 · completed
The study randomized 326 participants and used quadruple masking with placebo and tirzepatide comparator arms; its primary endpoint was the clinical outcome of percentage change in body weight. Because the primary comparison has not yet been reported, it cannot establish whether GZR18 met its efficacy objective.
Next expected readout: June 2027 · NCT07150975 (registry estimate)
TG103
Developed by CSPC Pharmaceutical Group
NCT05997576 · Phase 3 · completed
The study was randomized, double-blind, and placebo-controlled, with 675 participants and clinical primary outcomes measuring weight loss. However, no trial results are posted, so whether the primary endpoints were met cannot be determined.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR18's landscape · TG103's landscape